Discounted Cash Flow Calculation for GTSM:4120 using Dividend Discount Model Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future dividends to their present value. This
approach is used for finance firms where free cash flow is difficult to estimate
(e.g. Banks/ Insurance firms).
If the firm does not pay the majority of its earnings out as a dividend this
method will often arrive at a value significantly lower than the share price.
The current share price of
is above its future cash flow value.
Often investors are willing to pay a
for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Orient EuroPharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orient EuroPharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Orient EuroPharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Orient EuroPharma's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
Unable to compare Orient EuroPharma's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Unable to determine if Orient EuroPharma is high growth as no earnings estimate data is available.
Unable to determine if Orient EuroPharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Orient EuroPharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
1/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Orient EuroPharma's finances.
The net worth of a company is the difference between its assets and liabilities.
Orient EuroPharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Orient EuroPharma's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Orient EuroPharma's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 2.2x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Peter Tsai has been the President and Chief Executive Officer of Orient Europharma Co., Ltd. Mr. Tsai serves as the Chairman of Orient Pharma Co., Ltd. and Orient Europharma Co. Ltd. Mr. Tsai studied frm Dept. of Chinese Literature at Soochow University.
Insufficient data for Peter to compare compensation growth.
Insufficient data for Peter to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Chief Financial Officer
Director of Human Resources & Administrative Division
Consultant & Director
Board of Directors
Consultant & Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs. The company offers prescription medicines for cardiovascular, immunology, metabolism, neurology, gynecology, respiratory, and cancer treatment. It also distributes nutrition and baby care products, such as milk and nutritional supplements under the Babecare, Karihome, and Ostricare brands; and healthcare supplements, including nutritional supplements under the Ostricare brand and thermal water for the treatment of oral and periodontal diseases under the Buccotherm name. In addition, the company sells dermo-cosmetic products under the AGLab, HYABELL, HALab, ISISPHARMA, and Bio-Oil brands, as well as infant skin care products under the Mister Baby brand. Further, it develops CryoTek, a cryopreservation technology; and retinal prosthesis systems. Additionally, the company engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; NC-6004, a platinum-based micelle chemotherapeutic drug that is in Phase III clinical study; ASC-J9, a molecular chemical entity drug that has completed Phase III clinical study for androgen receptor degradation; and 2ccPA, a natural derivative of phospholipid, which is in Phase I clinical study. Orient EuroPharma Co., Ltd. was founded in 1982 and is based in Taipei, Taiwan.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.